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by Xingchen Zha 
 




Programmed death-ligand 1 (PD-L1) is a type 1 transmembrane protein that has 
been reported to play a vital role in mediating suppressed immunity. The interaction 
between PD-L1 and PD-1 delivers a negative signal that reduces the proliferation of 
these T cells and induces apoptosis at the same time. Antibodies that can block the 
Programmed death-ligand 1 (PD-L1) on tumor cells have been shown to alleviate 
cancer-induced immunosuppression. While antibodies have a great potential in various 
therapeutic uses, many drawbacks such as the high cost of production, huge molecular 
size, and poor permeability impose restrictions on the extensive use of full-length 
antibodies. These limitations have necessitated research for finding alternatives to 
antibodies, such as peptides, that have lower molecular weight and similar properties as 





In this study, a novel approach based on molecular interactions of the PD1-PD-
L1 complex was developed to design peptides against PD-L1 using Knob-Socket model 
as basis. Three generations of peptides, α-helix, over-packed and salt bridge function 
peptides, were designed. All designed peptides were docked in the Molecular Operating 
Environment (MOE) and the AutoDock Vina software for the docking energy and the 
detail interaction information. Synthesis and characterization of selected peptides were 
performed after simulation studies. Surface Plasmon Resonance (SPR) studies showed 
that α-helix and over-packed peptides can’t bind to the PD-L1 protein with no response 
on sensorgrams, while peptides with salt bridge function had a higher binding response 
than those two generations of peptides. In confocal microscopic studies, PD-L1 positive 
breast cancer cell line MDA-MB-231 was used to determine the binding specificity of 
the salt bridge function peptides to PD-L1 in vitro, while another breast cancer cell line 
(MCF-7, without PD-L1) was used as a control. After incubation with peptides, 
significant fluorescence intensities were detected on the MDA-MB-231 cells, while only 
background fluorescence was observed on MCF-7 cells. 
In conclusion, this study demonstrated that peptides against PD-L1 designed 
using the Knob-Socket model and molecular interaction between PD-L1-PD1 complex 
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Chapter 1: Introduction 
 
Cancer is a category of diseases caused by uncontrolled cell division and growth 
with the ability to invade and destroy other parts of the body [1,2]. There are many 
treatment options for cancer such as chemotherapy, radiation therapy, targeted therapy, 
and immunotherapy. Chemotherapy is the predominant treatment for cancer and usually 
comes with one or more cytotoxic anti-cancer drugs [3]. Ideally, these traditional 
antineoplastic drugs such as 5-fluorouracil and cyclophosphamide can kill rapidly 
dividing cancer cells but not the normal cells. However, the lack of tumor selectivity and 
low potency impose restrictions on those drugs in chemotherapy. To overcome the 
potency problem, more effort was put into the discovery of natural sources for efficient 
drugs such as auristatins. However, the selectivity of these drugs, which could lead to 
serious toxicity during the treatment, was still the significant problem for chemotherapy 
[4].  
Targeted therapy is a more specific therapy compared to the conventional 
chemotherapy which has effects on both the fast-dividing cancer cells and normal cells. 
Currently, targeted therapies are widely performed for breast cancer, melanoma, 
lymphoma, and other types of cancer [2]. There are two types of targeted therapies, 
active targeted therapy and passive targeted therapy. Passive targeting therapy was 




accumulation on normal cells but selective accumulation on cancer cells. The 
improvement selectivity was attributed to the increased permeation and retention 
function [5,6]. Correspondingly, the treatment of drugs used for their interaction 
specifically with molecular targets associated with cancers is called active targeted 
therapy. The specific interaction can be used in both the cancer growth and spreading 
stage.  
1.1 Cancer immunotherapy 
Cancer immunotherapy uses the immune system itself to treat cancer [7]. In the 
past few decades, immunotherapy has become a significant way of treating different 
types of cancer. Similar to targeted therapy, immunotherapies consist of active, passive, 
and hybrid therapy. The cancer cell surface has molecules called tumor-associated 
antigens, which can be determined by the immune system. Both active and passive 
immunotherapies can take advantage of those molecules in guiding the targeted 
response. 
Antibody therapy is one of the most important immunotherapies [8]. The 
immune system produces specific antibodies after detecting antigens on the cell surface. 
Antibodies can utilize the cell surface receptors as targets for the treatment of a wide 
range of cancers. An appropriate antibody could not only prevent the interference from 
tumor cells but could also induce antibody-dependent cytotoxicity when it binds to a 
targeting cancer antigen. All these functions could induce cell apoptosis and limit the 
cancer development. There are many approved antibodies for immunotherapy on the 




rational designing of a novel antibody for immunotherapy has a significant impact on 
cancer study. 
1.2 Antibody 
Many immunotherapeutic regimens involve antibodies. Antibodies are a key 
component of the adaptive immune response and play a central role in both recognizing 
foreign antigens and stimulating an immune response. Antibodies are Y-shaped proteins 
mostly produced by plasma cells and are composed of two regions: an antigen-binding 
fragment (Fab), which binds to antigens, and a Fragment crystallizable (Fc) region, 
which interacts with Fc receptors that are expressed on the surface of different immune 
cell types including macrophages, neutrophils, and natural killer (NK) cells. 
1.2.1 Structure of an antibody. As can be seen in Figure1.1, antibodies consist 
of three parts that are combined by disulfide bonds. The two arms of the antibodies 
account for the variable region (V) that is responsible for the binding of the antigen. In 
the variable region, there are regions called complementarity-determining regions 
(CDRs) that determine the binding specificity of antibodies. The constant (C) region 
with less variability is the last part of the antibodies and can bind to other immune 
molecules in the immune system. Many physiological functions such as lysis of cells 
and recognition of immune particles need the involvement of the C region of an 
antibody [9-11]. 
Antibodies consist of heavy chains and light chains. Heavy chains have the 
following five isotypes: Immunoglobulin A (IgA), Immunoglobulin D (IgD), 




Immunoglobulin A (IgA) is an antibody that is distributed in mucous membranes 
and plays a critical role in the immune system. Mucosal membranes produce more of 
IgA than all the other types of antibodies [12]. More than three grams of IgA are 
generated in the intestinal lumen, which takes up to 15% of all immunoglobulins 
[13,14]. Immunoglobulin D (IgD), with molecular weight 185kDa, is an antibody that is 
found in the plasma membranes of B-lymphocytes and the blood serum. The half-life of 
IgD is 2.8 days [15]. Additionally, IgD can activate the antimicrobial function which 
results in an increased immune surveillance [16]. Immunoglobulin E (IgE) is a type of 
antibody that is secreted by plasma cells. IgE plays a vital role in protecting the immune 
system from parasites such as helminths [17] (for example, Fasciola hepatica) and 
Schistosoma mansoni [18-20]. It can also bind to the receptors on platelets and 
eosinophils resulting in the activation of the immune system [21]. Immunoglobulin M 
(IgM) is the largest antibody produced by vertebrates. It is the first antibody involved in 
the response to an antigen [22,23]. Immunoglobulin G (IgG) is also generated by plasma 
B-lymphocytes. IgG is a type of antibody with a molecular weight around 150kDa, 
making up approximately 75% of the serum antibodies in humans [24]. IgG is also the 
most common type of antibody in the human immune system [25]. IgG molecules with 
two antigen binding sites are synthesized and released by plasma B cells. IgG can 
protect the body from an infection by recognizing and binding pathogens such as viruses 
and bacteria. Antibody-dependent cell-mediated cytotoxicity (ADCC) will be performed 












1.2.2 Binding between antibody and antigen. The antigen-antibody interaction 
mechanisms have been studied by various models for a long time [16, 27]. The body can 
be protected from harmful foreign molecules, such as pathogens, by the antigen-
antibody interaction. Antibodies can bind to antigens with high specificity and affinity in 
the blood, and then, the antigen-antibody complex is transported for deactivation.  
In 1952, Richard J. Goldberg from the University of Wisconsin developed the 
first correct definition of the antigen-antibody interaction [28,29]. It is also called the 
"Goldberg's theory" [30]. 
The flexibility of antibodies has been studied by scientists for a long time. Many 
different techniques such as fluorescence depolarization and X-ray crystallography have 
been used to determine the flexibility of the antibodies’ conformation [24]. To bind with 
an antigen, the constant domain of an antibody can change dramatically in the X-ray 
crystallography studies [26,31,32]. 
Each antibody can bind to one or multiple specific antigens based on the 
conformational flexibility. Manivel V et al. proved this mechanism based on the 
thermodynamic analysis [33]. Additionally, James et al. also determined the 
conformational flexibility of an antibody based on their research through 
crystallographic studies and the results showed that an antibody can bind to different 
antigens [34]. 
For the antibody-antigen interaction, tyrosine and tryptophan are abundant on the 
binding interfaces while less charged residues such as glutamate, lysine except for 




antigen for its hydroxyl group. Arginine can build hydrogen bonds and salt bridges 
based on its guanidinium part and three hydrophobic methylene carbons [35,36].  
However, not all the six CDRs have a connection with the antigen on the 
antigen-antibody interface. It is known that a minimum of four CDRs can bind to 
antigens [37]. Camelid single-domain antibodies, however, can bind to antigens though 
it has only two CDRs in its nanomolar ranges [38]. VH CDRs have more extensive 
interaction with antigen than VL CDRs [39]. Besides, some antigens such as peptides 
with a grooved contacting surface can bind to special sockets on the antibodies, which 
are different from the large protein antigens with planar surface [40].  
The binding of an antibody to its antigen is determined by affinity and 
specificity. The binding can be reversed and determined by the reactants concentrations. 
The antibody-antigen complex has a balance rate between formation and dissociation at 
the equilibrium phase. An affinity constant (KD) can be calculated based on the associate 
and dissociate rate constants. The high affinity of the antibody-antigen complex usually 
comes with the small KD. Normally, KD values of antibodies are in the range of 10
-6 to 
10-9. Antibodies with KD values in the low nanomolar range (10
-9) can be considered as a 
high affinity. Additionally, the specificity of the binding is attributed to the specific 
chemical structure of each antibody. Some small residues in the CDR1 and CDR2 of VH 
determine the binding specificities of the individual antibodies. The principles of 
specificity of the antigen-antibody interaction are valuable in the clinical laboratory for 
diagnostic purposes. The most basic application is in the determination of the ABO 




technique for infection with different pathogens, such as helminth parasites, HIV, and 
microbes. 
1.2.3 Development and categories of an antibody. In 1890, Emil von Behring 
and Shibasaburo Kitasato built a theory for antibodies. They found that infected animals 
suffering from diphtheria can be cured by the transfer of therapeutic serum from 
immunized animals [42,43]. Behring won the Nobel Prize in 1901 for the work in 
potential treatment in humans [44]. In 1900, the side-chain theory was developed by 
Paul Ehrlich, in which he proposed the hypothesis that side-chain receptors on cells can 
interact with a given pathogen. In his model, he assumed that an antibody can bind to 
foreign molecules called antigens and activate the complement pathway. The ‘lock and 
key’ theory developed by Emil Fischer came to the same conclusion as this model 
[45,46]. In 1948, Astrid Fagraeus proposed that an antibody was secreted by plasma B 
cells, and later in 1957, the clonal selection theory was given by Frank Burnet and David 
Talmage [47]. This theory was different from the model developed by Linus Pauling in 
1940 and stated that the antigen acted as a template for the antibody [48].  
Gerald Edelman and Rodney Porter won the Nobel Prize jointly in 1972 for their 
independently publishing of the molecular structure of antibodies in 1959 [49-51]. The 
first antibody fragment atomic resolution structure was published in 1973 [52]. 
Furthermore, the modern research of antibodies began based on the discovery of 
monoclonal antibodies by Georges Köhler and César Milste in 1975 [53]. 
An antibody can be produced from many different systems such as yeast bacteria 




bacteria such as Streptomyces and Escherichia coli. Only simple media was needed for 
protein growth with a range between 1 to 300 mg/L from the bacteria system [54]. But it 
is impossible to perform further modifications and collect full-size antibodies from the 
bacteria system. Additionally, expression levels of protein will reduce due to the loss of 
plasmid during bacterial culture. 
Yeast is another production, but inefficient, system for antibodies. Each liter of 
yeast medium could only generate few microgram antibodies until the 1980s [55]. Then, 
the methylotrophic yeast was developed, which produced antibodies with an increased 
productivity of 100 milligrams per liter yeast [56]. 
More complicated proteins such as full-size antibodies can only be obtained from 
the mammalian cells system. However, the high cost of the cell culture media and 
instruments impose restrictions on the development of mammalian cells system [57,58]. 
Therefore, it is better to obtain economically complex recombinant proteins from 
transgenic plants and animals instead of the traditional mammalian cells system. 
During the past several decades, great progress has been made in the field of 
antibody discovery and therapy with a total of over 300 unique monoclonal antibodies 













Figure 1.3 Evolution of therapeutic antibody technology.
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1.2.4 Polyclonal and monoclonal antibodies 
1.2.4.1 Polyclonal antibodies. Polyclonal antibodies (pAbs) are generated by 
different B cell lineages within the body while monoclonal antibodies (mAb) are only 
secreted by a single cell lineage. Polyclonal antibodies are a mixture of immunoglobulin 
molecules that bind to a specific antigen, each identifying a different epitope. 
  Polyclonal antibodies with different specificities and affinities are stable in a pH 
and salt concentration range [59]. Compared to other mammals producing polyclonal 
antibodies, the rabbit is the most significant production source of polyclonal antibodies 
for its low cost of maintenance and simple handling. Polyclonal antibodies are generally 
obtained by immunizing animals through intradermal and subcutaneous injections. The 
immune response was increased by using antigens with adjuvants such as bovine serum 
albumin [60]. 
1.2.4.2 Monoclonal antibodies. Monoclonal antibodies (mAb) are made by 
identical immune cells that are all clones of a unique parent cell. Monoclonal antibodies 
are homogenous and can bind to the same epitope. These monoclonal antibodies have 
similar immunochemical function due to the derivation of a single B cell clone of one 
animal while polyclonal antibodies bind to multiple epitopes and are generated by 
several different plasma cell lineages. Most monoclonal antibodies are obtained from 
rabbits and mice. By changing the therapeutic targets of one single monoclonal antibody 








1.2.5 Limitations of current antibody. As the pharmaceutical market in the 
world continues to expand, biopharmaceutical products such as therapeutic mAbs play a 
more significant role in cancer treatment. Approximately 60% of biopharmaceutical 
sales is attributed to monoclonal antibody products, and these products have grown to 
almost $90 billion in the past three years. A worldwide sales of monoclonal antibody 
products will take place in the future. However, getting treated with mAbs still has side 
effects such as tumor lysis syndrome and anaphylaxis [61]. 
Poor tumor permeability is another limitation of antibodies regardless of the 
adverse effects of mAbs. In the tumor microenvironment, the number of functional 
lymphatic vessels are not sufficient enough to transport the macromolecules such as 
mAbs [62]. The potential of an antibody treatment is reduced since it is difficult for 
mAbs to penetrate deeply into the tumor microenvironment. 
Additionally, the mAbs treatment currently available on the market is very 
expensive. The average annual cost of an mAb treatment was $96,731, and the 
Herceptin costs for the treatment was $43080 per year [63]. The production cost and 
development time also determine the application of antibodies. It took about 10 years for 
a mAbs to come to the market including the discovery and research time. In addition to 




1.2.6 Antibody alternatives. Since mAbs have many disadvantages as 
mentioned above, alternatives to antibodies have been created for the market. These 
molecules, with lower molecular weight, usually have a similar function such as binding 
specificity, affinity, and tissue penetration. These alternatives include Fab, nanobodies, 
single chain fragment variable (scFv), antibody mimics [64,65], and so on. Furthermore, 
the research and screening time of antibody alternatives is shorter than a monoclonal 
antibody. Compared with the traditional mAbs, these molecules with lower molecular 
weight can easily penetrate to the tumor site and bind to an antigen. 
1.2.6.1 Single chain fragment variable (scFv). Single chain fragment variable is 
a protein consisting of the variable regions of the heavy and light chains of 
immunoglobulins [66]. scFv can be employed to build molecules for different purposes 
due to the retainment of the binding specificity and affinity of a full antibody [67-69]. 
However, scFv with a molecular weight around 25kDa has a limitation of lower half-
life, making it difficult to be used in the market [70]. Two scFvs can be connected by a 
peptide linker or a disulfide bond [69,71-73]. E. coli bacterial with an ability to generate 
foreign protein in a large amount can secrete scFv at a high speed [74]. Generally, 
mRNA is isolated from the hybridoma [75-77] or spleen cells from immunized mice 
[78,79] or B lymphocytes [80,81] and is reverse transcribed into DNA followed by gene 
amplification by the PCR technique. The only issue with this approach is that some 
protein lacks certain conformation due to the limited folding capacity of the E. coli 




1.2.6.2 Antibody mimic. Antibody mimic is a molecule that can bind to a protein 
with specificity and affinity. The molecular weight of an antibody mimic is less than 10 
kDa [84]. Antibody mimic can bind to an antigen with no risk of ADCC and CDC 
because of the lack of constant region of an antibody. There are many different 
approaches such as phage display, mRNA display, and yeast two-hybrid system for the 
development of antibody mimics [85,86]. 
In 1998, the first antibody mimic was designed to bind to TNF-α by performing a 
phage display [87]. However, the binding affinities of the isolated peptides were too low 
for them to be used for treatment. A lot of effort has been put on the discovery and 
screening for antibody mimics with KD values in the picomolar to the millimolar range 
[88,89]. The three-amino-acid motif RGD, developed by a phage display technique, is 
one of the most promising examples among them. This motif with a KD of 0.8 nM can 
bind to the αVβ3 integrin that forms the tumor vascular endothelial cells [90]. 
Chemical synthesis is another feasible approach to obtain antibody mimics. 
Before synthesis, a mass of molecular docking should be done between the screening 
peptides with a random sequence and a library of thousands of human proteins [91]. Rod 
Balhorn et al. discovered selective high-affinity antibody mimics that target leukemia or 
lymphoma through molecular docking [92]. However, all docking based on these 
screenings are tedious and time-consuming due to the trial-and-error principle. 
Therefore, a rational design of peptides based on the molecular interaction between 




1.3 Programmed Death-Ligand 1 
Programmed death-ligand 1 (PD-L1) is a 40kDa type 1 transmembrane protein 
that has been studied to play a critical role in mediating the suppressed immune function 
during specific events such as tissue allografts and autoimmune diseases. This molecule 
was named as PD-L1 due to its identification as a ligand of PD-1 after its first 
characterization by Mayo Clinic as an immune regulatory molecule, B7-H1 [93]. The 
immune system takes the response to foreign antigens that are relative to both exogenous 
and endogenous danger signals, which causes an activation and proliferation of the 
antigen-specific T cells. The interaction between PD-L1 and PD-1 delivers a negative 
signal to these T cells and results in the reduced proliferation of T cells [94]. 
Blockade of PD-L1 can limit the growth of tumors in the presence of immune 
cells while most cancer cells have the ability to express high levels of PD-L1. A 
conclusion can be made that tumor cells can escape immune attack with PD-L1 [95]. 
PD-L1 can modulate activation or inhibition upon binding with its receptor PD-1, which 
is located on activated T cells, B cells, and myeloid cells. Said et al. found that PD-L1 
can induce IL-10 production when interacting with PD-1 which is upregulated on 
activated CD4 T-cells [96]. 
It is reported that the upregulation of PD-L1 could help cancers to escape attack 
from the host immune system. Antibodies that can block PD-L1 on tumor cells have 
shown the ability to alleviate cancer-induced immunosuppression [97]. Many PD-L1 
inhibitors such as durvalumab, atezolizumab, and avelumab are in development as 




L1 has been considered as a potential target for a receptor-mediated delivery system of 






Figure 1.5 Mechanism of PD-L1 delivers T Cell Suppression and Tumor Cell Survival [100].
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1.4 Statement of the Problem 
Antibodies have been commonly used as reagents to recognize antigens or 
proteins in life science research due to their binding specificity. Recently, several 
antibodies have been successfully developed for therapeutic uses. However, extensive 
uses of antibodies are limited by their high cost of production, long production period, 
and poor stability. These limitations have necessitated research for finding antibody 
alternatives with lower molecular weight and similar properties as antibodies but without 
the limitations of the lengthy and complicated approach of producing antibodies. Some 
examples of these efforts include fragment antigen binding (Fab) and scFv, or synthetic 
antibody mimics. Though these molecules have lower molecular weight when compared 
with antibodies, they still have the disadvantages of tedious and time-consuming 
processes, the uncertainty of the outcome, and high costs of production. A rational 
design of molecules that can mimic the antibody-antigen interaction based on the 
molecular interaction and Knob-Socket model can be considered as a viable approach 
for antibody alternatives. In this study, we proposed an approach to design peptides 
against a target without involving massive experimental screening trials. 
1.5 Hypothesis 
Rationally designed peptides that specifically bind to PD-L1 based on molecular 
interactions between the ligand-receptor and Knob-Socket model. 
1.6 Specific Aims 
The objective of this dissertation research is to design, synthesize, and 




Knob-Socket model. To achieve the research objective, the specific aims are described 
as following:  
1. To design peptides based on the Knob-Socket model and protein-protein 
interaction. Peptides which can specifically bind to the PD-L1 and scrambled 
(control) sequence peptides are designed. 
2. To perform computer simulation studies and to determine the number of 
interactions, docking energy, and binding position by Molecular Operating 
Environment (MOE) and AutoDock Vina software. Selected peptides based on 
these parameters are utilized for future studies in vitro. 
3. To synthesize and characterize peptides. Designed peptides and scrambled 
sequence peptide with and without the FITC conjugation are synthesized using 
the solid phase synthesis method. The purity and mass to charge ratio will be 
determined by the high-performance liquid chromatography (HPLC) and mass 
spectrometer. 
4. To study the in vitro binding specificity and affinity of peptides to PD-L1. The 
binding affinity and specificity will be determined by performing the Surface 











Chapter 2: Design and Computational Studies of Peptides 
2.1 Introduction 
In life sciences, antibodies are commonly performed to bind to different targets 
with significant affinity and specificity in various areas such as therapeutic agents. When 
compared with antibodies, peptides are much smaller in mass and size. Peptides can 
simulate the interaction between antibodies and antigens with a small molecular weight. 
Additionally, due to their small structure, they can penetrate tumor tissues easily and are 
unlikely to trigger immunogenicity [101]. 
Molecular modeling is performed to predict the structure of biological molecules 
and simulate the binding functions between the receptor and ligand in biological and 
chemical systems. In this part, peptides are designed against the target based on the 
molecular interactions between the antibody and antigen instead of complicated 
experimental screening trials.  
Molecular Operation Environment (MOE) is widely used as a drug discovery 
software in different fields of molecular modeling, protein and antibody modeling, and 
fragment and structure-based designing. The docking program in MOE can be 
performed to mimic the interaction between two molecules based on their crystalline 
structures. The possible orientation of two molecules can be obtained and analyzed in 
the docking program. MOE can be used to screen the molecules based on the estimated 




energy suggesting a possible interaction between two molecules. Also, a map with 
detailed interaction on the interface between the two molecules can be determined by the 
ligand interaction function in MOE. In other words, we can identify and select the 
specific amino acid sequences in the binding interface that are significant for the 
receptor to bind ligands. 
AutoDock Vina is another screening software for molecular modeling which can 
perform to determine the average accuracy of the binding mode predictions. It is an 
important program for molecular docking and virtual screening. Vina performs a 
sophisticated gradient optimization approach in its local optimization procedure. The 
calculation of the gradient effectually offers the optimization algorithm a direction from 
a single evaluation. By using multithreading, multiple CPUs or CPU cores can be 
employed by Vina to speed up the calculation in screening molecules. After docking in 
the AutoDock Vina, designed peptides can be screened based on the binding position 
against the PD-L1 protein. Only peptides bound to the designed binding interface from 
PD-L1 can be considered as important candidates. 
PSIPRED is a precise and simple secondary structure prediction approach, 
incorporating two feed-forward neural networks which carry out an analysis on output 
got from PSI-BLAST (Position Specific Iterated - BLAST). The secondary structure of 
peptides that we designed can be predicted by PSIPRED. 
The interaction between PD1 and PD-L1 has been extensively studied by 
scientists [102,103]. The three-dimensional structures of the different PD1-PD-L1 




the Protein Data Bank (PDB). Core amino acids from the binding interface of the PD1-
PD-L1 complex can be collected and employed to design the peptides for PD-L1 after 
analyzing the binding details. 
The interaction between the novel peptide and PD-L1 was optimized by using 
the Knob-Socket model developed by Joo et al. [104]. The packing between the 
interactions of two molecules can be analyzed and explained by this model in a 
simplified and straightforward approach. When it is compared with the other packing 
models, the Knob-Socket model can be used to determine and optimize all kinds of 
packing in the secondary structure [105]. In this model, Knob-Socket is defined as a 
four-residue tetrahedral: one knob B in one secondary structure packed into a three 
residue H: YX socket presented on the other secondary structure (Figure 2.1). The X 
and Y are consecutive residues that pack with the covalent peptide bond (continuous 
black line), where the hydrogen bond (broken red line) connects X and H. The H and Y 
residues only connect by their side-chain interactions. Additionally, three types of 
sockets were provided in the Knob-Socket model: a free socket with no packing knob, 
filled socket with a packing knob, and a non-socket. The amino acid propensities 
determine the packing strategy for choosing the binding peptide sequences in these three 
types of socket. 
A two-dimensioning map can be obtained with the information of sockets formed 
on PD-L1 and specific binding knobs from PD1 in the principle of the Knob-Socket 




filled into sockets on PD-L1 can be determined and can be used for optimizing and 
designing the peptides against PD-L1. 
In this chapter, by using the Knob-Socket model, the interaction between 
different PD1-PD-L1 complexes was analyzed and studied for the designing of the novel 
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(a) A two-dimensional representation of the Knob-Socket model shows that the three residues  
X, Y, and H in the socket are all packed against a knob residue B from the other secondary structure.  
(b) The four-residue motif is arranged in the tetrahedral structure. All residues are represented by spheres.  
The knob residue B connects to all the three socket residues only through side-chain interactions.  








UCSF-Chimera package (Version 1.10, San Francisco, CA, USA), MOE 
software (Version 2013.08) from Chemical Computing Group Inc. (Montreal, QC, 
Canada), AutoDock Vina from Scripps Research Institute (La Jolla, CA, USA). 





2.3.1 Design of peptides. Peptides were designed based on the crystal structure 
of PD1-PD-L1 and the Knob-Socket model. The crystal structures (PDB 3SBW and 
5IUS) were analyzed to determine which residues in PD-1 have maximum interaction 
with the PD-L1 epitopes. For the first and second generations of peptides, the PD-L1 
protein surface was identified to provide sockets in the two-dimensional map with 
binding knobs from PD1 by analyzing the crystal structure PDB 3SBW. 
Correspondingly, crystal structure PDB 5IUS was used for designing the third 
generation of peptides. Each amino acid knob residues from the PD-1 is in contact with 
the socket formed by the three amino acid residues on the PD-L1 surface. Based on the 
probability of packing the amino acid knob to a different socket, peptides were designed 
in an approach of linking the identified knob. Franking amino acids can be used to fill 
the space when the distance between two residues is a lot. Different peptide sequences 
can be designed by combining the amino acids from the list of possible knobs with 
various sockets. For the α-helix peptides, 12 different peptide sequences were designed 
in 25 amino acids length. To increase the stability and build an α-helix structure, several 
amino acids were added to the start and end of the peptide sequences. The key amino 
acid knobs from α-helix peptides were used to design the over-packed peptides with a 13 
amino acids length. Correspondingly, the third generations of peptides, the peptides with 
salt bridge function, have 67 peptides sequences including one scrambled sequence 




2.3.2 Secondary structure prediction for peptides in alpha helix design. The 
secondary structure of peptides in alpha helix design was predicted by PSIPRED. 
Several UCL structure prediction techniques were combined into one location by the 
PSIPRED Protein Sequence Analysis Workbench. The results of the prediction were 
received after submitting a protein sequence. 
Peptides with high ratio of alpha helical structure and confidence of prediction 
were then selected for further experiments and were docked in the AutoDock Vina to 
check whether they could bind to the designed part of the target protein for further 
screening. 
2.3.3 Computer modeling studies. The crystalline structure of the PD-PD-L1 
complex that was downloaded from the protein databank with PDB ID:3SBW and 5IUS 
was analyzed in Chimera and optimized in MOE. Molecular Operating Environment 
(MOE) was performed to determine the binding interface between the ligand and 
receptor. The binding socket from PD-L1 and the amino acid knobs from PD1 were 
assigned for the docking study by the atom selector. We can obtain the detailed 
interaction map between PD-1 and PD-L1 by ligand interaction simulation. Furthermore, 
core amino acid sequences for the design of peptides can also be analyzed and 
determined by the direct interaction sequence from ligand interaction simulation. 
Designed peptides were screened by utilizing the Molecular Operating 
Environment (MOE) and the AutoDock Vina software. After performing energy 




MOE software to calculate the binding energy. The lower (negative) suggests better 
binding.  
Peptides with more number of interactions, preserved interactions, and lower 
docking energy were then selected for further experiments and were docked in the 
AutoDock Vina to check whether they could bind to the designed part of the target 
protein for further screening.  
2.4 Results and Discussions 
2.4.1 Design of peptides. Peptides were designed based on the PD1-PD-L1 
crystal structure and the Knob-Socket model. Taking the frequency data of knob and 
sockets from Figure 2.2, the design of peptide sequences was determined by the 
propensity of preferable knobs to sockets. The map and ribbon diagram of the PD-L1 
surface bound by PD1 for α-helix and over-packed peptides are shown in Figure 2.3. 
The knob positions from the ligand are represented as spheres. The pink color represents 
knobs from PD1 in a covalent bond. Correspondingly, the map and ribbon diagram of 
the peptides with the salt bridge function is shown in Figure 2.4. The side-chains of the 
amino acids are also displayed, and the knob positions from the ligand are shown as 
spheres. The orange color represents knobs from PD-1 in a covalent bond and red 
represents the salt bridge function. 
For the α-helix and over-packed peptide sequences, the packing interface lattice 
diagram consisting of knobs and sockets is shown in Figure 2.3 (left). The filled sockets 
are in grey and free sockets with no binding knobs are in yellow. The knobs are 




Based on the mapping data, the key amino acid sequences are designed as shown 
in Figure 2.5. The α-helix peptide sequences are designed based on these 13 amino 
acids. To increase the stability and build an α-helix structure, several amino acids are 
added to the start and end of the peptides. There are 25 α-helix amino acids in total. 
Furthermore, over-packed peptides are designed by the 13 key amino acids as shown in 
Figure 2.6. 
Additionally, the sequences of third generation peptides are shown in Figure 2.7. 
Arginine was chosen as the first amino acid for its basic side chain that can bind to the 
acidic part of the protein shown on coulombic surface coloring; “a double anchor” with 
glutamic acid and aspartic acid. The second amino acid, lysine, was also chosen because 
it can bind to glutamic acid. The third, fifth, and seventh amino acids were selected 
based on the propensity of the Knob-Socket model. Proline was used to give a turn off in 
the fourth position. For the sixth position, serine was added to increase the hydrophily of 
the peptide. Glycine was used in the eighth position as a franking amino acid. Glutamine 
was used for its propensity in socket ADY. Threonine and glutamic acid were used for 
its salt bridge. Histidine had a connection with aspartic acid. Knobs in pink and red that 
have high preference such as Leu (L), Glu (E), Phe (F), and Tyr (Y) were filled in the 




Figure 2.3 Mouse PD-1 mutant and human PD-L1: Ribbon diagram of the PD1-PD-L1 interface (right) and  





Figure 2.4 High affinity mouse PD-1 and human PD-L1: Ribbon diagram of the PD1-PD-L1 interface (right)  





Figure 2.5 Mouse PD-1 mutant and human PD-L1: α-Helix Peptides designed based on the PD1-PD-L1  





Figure 2.6 Mouse PD-1 mutant and human PD-L1: Over-packed Peptides designed based  




Figure 2.7 High affinity mouse PD-1 and human PD-L1: Peptides with SB function designed  




2.4.2 Secondary structure prediction for peptides in alpha helix design. 
Peptides were selected based on the result of the ratio of alpha helical structure and 
confidence of prediction. The sequences and prediction results of α-helix peptides are 
shown in Figure 2.8. PDL1-01-25MER was chosen based on the high ratio of alpha 

























2.4.3 Computer modeling studies. Peptides were selected based on the result of 
the total number of interactions, preserved interactions, and docking energy. The 
sequences and docking results of over-packed peptides are shown in Table 2.1. For over-
packed peptides, PDL1-06-13MER was chosen based on the lower docking score. For 
the peptides with salt bridge, PDL1-P13-01, PDL1-P13-28, PDL1-P13-40, and PDL1-
P13-55 were selected based on their lower binding energy as shown in Table 2.2. 
A conclusive docking was performed by AutoDock Vina in terms of the total 
number of interactions, preserved interactions, and docking energy, and the results are 
shown in Table 2.3. The α-helix and over-packed peptides with a higher binding energy 
and with a less number of total and preserved interactions suggested poor binding 













Table 2.1 Docking results of over-packed peptides. 
Ranking Peptide No. Sequence Docking Score 
1 PDL1-06-13MER IAKARAQLEQFAS -11.11 
2 PDL1-07-13MER EARAIAQLRELFA -11.01 
3 PDL1-09-13MER EAAERAQYEQFLS -10.93 
4 PDL1-12-13MER LAKQIAEYRALLE -10.68 
5 PDL1-08-13MER LAKARAELAQFIK -10.66 
6 PDL1-01-13MER EARKIAELEQFLE -10.54 
7 PDL1-02-13MER EARERAEIEALLS -10.43 
8 PDL1-10-13MER EAKARAQYEQILA -10.36 











Table 2.2 Docking results of peptides with salt bridge function. 
Top 20%: 13 Ranking Sequence Results 
 1 PDL1-P13-28 -15.5482 
 2 PDL1-P13-14 -15.4521 
 3 PDL1-P13-53 -15.4139 
4 Run 4 PDL1-P13-31 -15.1848 
 5 PDL1-P13-1 -15.1122 
 6 PDL1-P13-32 -15.0183 
 7 PDL1-P13-45 -14.8636 
 8 PDL1-P13-11 -14.7244 
 9 PDL1-P13-62 -14.7051 
 10 PDL1-P13-55 -14.6899 
 11 PDL1-P13-8 -14.5711 
 12 PDL1-P13-60 -14.551 
 13 PDL1-P13-40 -14.5242 
    
 28 PDL1-P13-33 -14.0458 





Table 2.3 Peptides sequence with molecular modeling results. 
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IAKARAQLEQFAS -4.0           1        6 





RKIPLSIGQTHSE -5.6           2       11 
 PDL1-P13-28 RKFPLSKGQTHSE -5.5           3       15 
 PDL1-P13-33 RKFPSSFGQTHSE -4.7           2       10 
 PDL1-P13-40 RKIPHSKGQTHSE -5.4           2       11 
 PDL1-P13-55 RKVPHSIGQTHSE -6.1           6       12 
 PDL1-P13-X 
(control) 




AutoDock Vina was used to perform a second screening for the selected peptides 
from the MOE software. From the Figure 2.9, we can determine that only PDL1-P13-55 
can bind to the designed part of the target protein. 
In this study, a screening approach of potential molecules to a given target was 
evaluated by using the MOE and AutoDock Vina software. The optimized potential 
energy was used in docking software instead of the free energy of the protein. Three 
generations of peptides were designed based on the molecular interaction between PD-
L1 and PD-1 and were optimized by utilizing the Knob-Socket model. α-helix and over-
packed peptides selected from MOE suggested that these molecules might not bind to 
PD-L1. Besides, the third generations of peptides showed the binding preference against 
the PD-L1 protein, based on the docking results from MOE and AutoDock Vina. The 
binding between the designed peptides and PD-L1 still needed verification in 
experiments. Based on the docking results from MOE and AutoDock Vina, PDL1-01-
25MER, PDL1-06-13MER, PDL1-P13-01, PDL1-P13-33, PDL1-P13-28, PDL1-P13-40, 















Chapter 3: Synthesis and Characterization of Peptides for PDL1 
3.1 Introduction 
The established method for synthesizing peptides in the lab is known as solid-
phase peptide synthesis (SPPS) [106]. This method was developed by Robert Bruce 
Merrifield in 1963 [107,108] and it has frequently been used to synthesize different 
peptides and proteins. SPPS leads to high yields of pure products and saves more time 
than traditional synthesis such as liquid-phase peptide synthesis (LPPS). The advantages 
of this method are very impressive. In the replacement of a complicated isolation 
procedure, lots of time is saved for each intermediate product with a simple washing step 
[109]. Additionally, this technique is feasible as well for automatic peptide synthesizers 
that are commercially available. However, this method has the disadvantages of low 
output since there are many cycles of coupling and deprotection for each amino acid in 
the peptides synthesis and the intermediates cannot be purified after each coupling.   
The key feature of SPPS is the continuous attachment of amino acids to a solid 
support bead called resins. The chemical structure of the resin that we will use in the lab 
is shown in Figure 3.1 (called Wang resin). The hydroxyl group is the place of 
attachment to the C-terminal amino acid in the peptide chain. The rest of the peptide is 
then synthesized by coupling one amino acid at a time [106]. Wang resin will keep 




resins build a synthesis environment in which the peptide sequences being attached will 
not cross a filter in the synthesis vessel.  
 
 




Each amino acid has both an amine and carboxylic acid functional group, which 
would result in side recreation through the synthesis process. Therefore, it is significant 
to consider the protection strategies. 9-Fluorenylmethoxycarbonyl (Fmoc), used as the 
protecting group, is commonly used in the peptides synthesis experiment. The N-
terminal of each amino acid will be protected with Fmoc, and only the amino acid at the 




It is necessary to protect the side chain with protecting groups such as tert-
butyloxycarbonyl (Boc) and tert-butyl (tBu) to prevent degradation during synthesis. 
These protecting groups are stable enough in their basic conditions [107]. Additionally, 
these protecting groups are convenient due to their instability in acid and will be cleaved 
by the TFA in the final cleavage step. 
The first amino acid usually has an attachment to Wang resin. Therefore, the first 
step is removing the Fmoc group on the C-terminal amino acid by employing a base 
such as mild basic solution 20% piperidine in DMF. The second Fmoc-protected amino 
acid is then attached utilizing a coupling reagent such as diisopropylcarbodiimide (DIC) 
and 1-hydroxybenzotriazole (HOBt) to make the reaction. Besides, several other 
coupling agents such as 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HBTU), and 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HATU) that require a base for activation were 
employed with N, N-Diisopropylethylamine (DIPEA) in peptide synthesis. The 
completion of each reaction is analyzed and confirmed by the Kaiser test based on the 
different colors.  
After the final coupling and deprotection of the peptide, trifluoroacetic acid 
(TFA) can be used to cleave the peptide from the solid support. Peptides were separated 
by using ice-cold diethyl ether from the cleavage cocktail solution. The peptides can be 
characterized after lyophilization. Mass spectrophotometric techniques were used to 
confirm the molecular weight of peptides and high-performance liquid chromatography 




Circular dichroism (CD) is dichroism involving circularly polarized light, in 
other words, the differential absorption of left- and right-handed light. CD spectroscopy 
has a wide range of applications in many different fields, such as determination of the 
secondary structure of proteins. The far-UV CD spectrum of proteins can reveal 
important characteristics of their secondary structure. The typical CD spectrum of alpha-
helix, the beta-sheet, and random coil are shown in Figure 3.3. The alpha helix of 
proteins has CD spectral signatures representative of their structures. The secondary 
structure of peptides designed in α-helix method can be checked by CD. 
A series of peptides to PD-L1 will be synthesized by using the solid phase 
synthesis method. HPLC will be used for the purification of peptides and ESI-MS will 



















3.2 Materials  
All peptide synthesis reagents including Fmoc-Wang resins, amino acids, N, N’-
Diisopropylcarbodiimide (DIC), N, N-Diisopropylethylamine (DIPEA), 
triisopropylsilane (TIS), N-hydroxybenzotriazole (HOBT), 2-(1H-7-azabenzotriazol-1-
yl)-1,1,3,3 tetramethyluronium hexafluorophosphate (HATU), O-(Benzotriazol-1-yl)-
N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU), piperidine, and 6-
aminohexanoic acid (Ahx) were purchased from Chem-Impex International Ltd (Wood 
Dale, IL, USA). Solvents including dichloromethane (DCM), N, N’-dimethyl formamide 
(DMF), and Acetonitrile (ACN) were of HPLC grade from Fisher Scientific (Pittsburgh, 




Acros organics (Pittsburgh, PA, USA). Acetic anhydride was obtained from 
Mallinckrodt (St. Louis, MO, USA). Fluorescein isothiocyanate (FITC) was purchased 
from Calbiochem (San Diego, CA, USA). All chemicals and solvents were used without 





3.3.1 Synthesis of peptides. The peptides: PDL1-01-25MER, PDL1-06-13MER, 
PDL1-P13-1, PDL1-P13-28, PDL1-P13-33, PDL1-P13-40, PDL1-P13-55, and PDL1-
P13-X were synthesized by the solid phase peptide synthesis method using standard 
Fmoc chemistry (Table 3.1). First, the Wang resin (0.2 mmol scale) preloaded with the 
C-terminal end amino acid of these different sequences was preswelled in DMF for 20 
minutes, and the amino group of that amino acid was deprotected using 20% piperidine 
in DMF for 30 minutes. After washing with both DMF and DCM three times, the Fmoc 
protected amino acid was added with five equivalences of HBTU and HOBT and nine 
equivalences of DIPEA for three hours. The Kaiser test was performed to estimate the 
completeness of the coupling by observing the color of resin. The deprotection and 
coupling procedures were repeated until the last amino acid at the end of N-terminal was 
attached on to the resin. After every three coupling procedures, capping was performed 
to block the intermediates that cannot be washed away by using acetic anhydride and 
DIPEA in the DMF solution. At last, the cleavage of the peptide was conducted by 
adding the cleavage cocktail of TFA, phenol, deionized water, and TIPS in the ratio 
88:5:5:2 and reacting for three hrs. The TFA solution was added into ice-cold diethyl 
ether to precipitate the peptides. The diethyl ether and peptide mixture were kept at -
20˚C overnight to obtain the maximum amounts of products. Ice-cold diethyl ether was 
used again to collect the precipitate by centrifuging and washing it three times. After 




3.3.2 Synthesis of FITC-peptide conjugations. In confocal microscopy studies, 
FITC was commonly used to conjugate onto the N-terminus of the peptides as a 
fluorescent probe. The Ahx (6-aminohexanoic acid), protected by Fmoc, was used as a 
linker and was added to the N-terminus of the peptides using the same method as that of 
amino acids. Three equivalents of FITC were dissolved in anhydrous DMF with 10 
equivalents of DIPEA and agitated overnight in the dark. FITC-peptide conjugations 
were then cleaved from the resin by using the cleavage cocktail containing TFA, phenol, 
deionized water, and TIPS in the ratio 88:5:5:2 without the deprotection procedure. 
After three hours of shaking, the mixture was added into ice-cold diethyl ether to form 
precipitation. Ice-cold diethyl ether was used again to collect the precipitate by 
centrifuging and washing it three times. After that, the FITC-peptide conjugations were 




3.3.3 Characterization of all peptides and FITC-peptide conjugations. 
Peptides were characterized by MALDI-TOF (Shimadzu-Kratos PC Axima CFR V2.2.1) 
using α-Cyano-4-hydroxycinnamic acid (CHCA) as a matrix or Electro-Spray Ionization 
Mass Spectrometry (ESI-MS, Varian 320 ESI-triple-quadrupole mass spectrometer). 
Samples were prepared in methanol and water in a 1:1 ratio. The purity of all 
compounds was determined by high-performance liquid chromatography (HPLC), 
Agilent 1100 Series, using Agilent Zorbax SB-C18, 3.5µm, 4.6 × 150 mm, column. 
Water with 0.1% TFA (A) and acetonitrile with 0.1% TFA (B) were used as the mobile 
phase. Both analyzation and purification were performed in the same HPLC column by 
collecting the separated fractions, and then the peptides were lyophilized and stored at -
80˚C before further analysis. 
3.3.4 Characterization of secondary structure for peptides in alpha helix 
design. The secondary structure for peptides in alpha helix design were characterized by 
Spectra Manager Version 2 software in Jasco J-810 spectropolarimeter. Samples were 
prepared in methanol and water in a 1:1 ratio. 
3.4 Results and discussion 
All peptides were successfully synthesized by the solid phase peptide synthesis 
method. In the binding studies, these peptides without FITC will be tested with PD-L1 
protein using the Surface Plasmon Resonance (SPR) technique. To build the peptide 
chain, it is necessary to repeat deprotection and coupling protocols in the synthesis of 
these peptides. Most of the amino acids were coupled using five folds excess in three 




hours. HBTU, a stronger coupling agent with DIPEA, was performed to complete the 
coupling procedure instead of DIC when the amino acid was not conjugated to the resin. 
The presence of free primary amino groups was checked by the Kaiser test, which is a 
useful way to determine the completeness of a coupling step. The peptides were 
separated from the side products and other impurities by using HPLC with a 
hydrophobic C18 column after the cleavage step. It was necessary to add 0.1% TFA into 
the mobile phases since the behavior of some C18 columns greatly relied on strong ion 
pairing agents that could enhance the shape and resolution of the peak. Additionally, it 
was easy for TFA to volatilize and it had a low absorption within the detection 
wavelengths. The desired peaks were finally separated and purified. The final purity of 
the peptide is shown in Table 3.1 and HPLC peaks of all the peptides are shown from 
Figures 3.15 to 3.20. 
Different peaks were collected to identify and confirm by MS. All the peptides 
with or without FITC were characterized by ESI MS. The MS results showed the desired 
molecular weight of the peptides. The desired peptides with right molecular weight were 
obtained from the analyses of the mass spectrum. The MS spectra are shown from 
Figure 3.3 to 3.8. 
FITC labeled peptides were synthesized as well for cellular uptake studies by 
using the confocal microscopy technique. During cleavage, N-terminal FITC-labeled 
peptides undergo a cyclization, resulting in the development of a fluorescein followed by 
the removal of the last amino acid on the peptide. It is difficult to conjugate FITC onto 




which leads to an unexpected product. An alkyl spacer 6-aminohexanoic acid (Ahx) was 
added at N-terminus of the peptide, and then the Ahx group provided FITC with space 
which resulted in the acquiring of the desired product [112]. Additionally, the influence 
of FITC to the binding/function of peptides can also be reduced by the attachment of the 
Ahx group [113]. FITC labeled peptides were successfully synthesized based on the 
analyses of the mass spectrum. The MS spectra of FITC labeled peptides are shown 
from Figure 3.9 to 3.14. The MS results showed the desired molecular weight of the 
peptide and were confirmed by the products with their m/z values detected in ESI-MS. 
For all the FITC conjugated peptides, the final purity was checked by the HPLC analysis 
using the same methods mentioned before. The final purity of the FITC labeled peptide 
is shown in Table 3.1, and the HPLC peaks of all the FITC-peptides are shown from 
Figures 3.21 to 3.26. 
The secondary structure for peptides in alpha helix design was determined by 
Circular Dichroism. The CD spectrum of PDL1-01-25MER is shown in Figure 3.27. The 
results showed the desired figure but the low ratio of α-helical structure of peptide in 
alpha helix design. 
Peptides and FITC-peptides were successfully synthesized by using the solid 
phase peptide synthesis and were characterized by MS and HPLC. FITC was 
successfully conjugated to the N-terminus of the peptides. The binding specificity and 







Table 3.1 Sequence of peptides for synthesis 
    Peptides         Primary structure      MW           HPLC Purity 
[M+3H]3+       (%)        
PDL1-01-25MER 
 
    YGNLARKIAELEKLL- 
     AEAQQREALG 
697.3                 98 
PDL1-06-13MER      IAKARAQLEQFAS 478.4                  94 
PDL1-P13-01      RKIPLSIGQTHSE 550.2                  99 
PDL1-P13-28      RKFPLSKGQTHSE 505.8                  99 









     RKIPHSKGQTHSE 






502.4                  95 
717.7                  93 
673.4                  95 
670.9                  94 
669.9                  94 
660.3                  96 





































































Figure 3.16 HPLC chromatogram of PDL1-01-25MER




































Figure 3.17 HPLC chromatogram of PDL1-06-13MER 
 














































Figure 3.18 HPLC chromatogram of PDL1-P13-01 
 












Figure 3.19 HPLC chromatogram of PDL1-P13-28 












Figure 3.20 HPLC chromatogram of PDL1-P13-33 




















































Figure 3.21 HPLC chromatogram of PDL1-P13-40 















Figure 3.22 HPLC chromatogram of FITC-PDL1-P13-01 
 















Figure 3.23 HPLC chromatogram of FITC-PDL1-P13-28 






























Figure 3.24 HPLC chromatogram of FITC-PDL1-P13-33 













Figure 3.25 HPLC chromatogram of FITC-PDL1-P13-40 














Figure 3.26 HPLC chromatogram of FITC-PDL1-P13-55 














Figure 3.27 HPLC chromatogram of FITC-PDL1-P13-X 








































Chapter 4: In Vitro Binding Specificity, Affinity of Peptides to PDL1 
4.1 Introduction 
In the different areas of biomedicine, binding studies are significant and 
meaningful for biomolecules. The increasing attention to the antibodies results in the 
development of those binding methods. Specificity and affinity are the most important 
properties in binding studies. 
The binding specificity is one of the significant parameters of an antibody. For a 
biomolecule, it is probable that there is not only one site to bind with, referred to as non-
specific binding, and is the reason why drugs have side effects. It is unacceptable if a 
ligand doesn’t bind to its designated receptor. Therefore, it is necessary to focus on the 
binding specificity studies. 
Cell culture experiment is widely performed in binding specificity studies. The 
expression for the interested protein on the cell is provided, and cancer cells are known 
to overexpress certain receptors as compared to normal cells. Additionally, it is also 
convenient to observe the biological activities with other molecules on the cells [114].  
PD-L1 protein is found that overexpress on different cancer cells. In vitro, 
cellular uptake studies with fluorophore associated imaging methods are widely used to 
determine the binding specificity studies to PD-L1 in the lab. After incubating with cells, 
the FITC labeled peptides can be detected and analyzed based on their localization and 




known to provide images with a better resolution and reduced background signal [115]. 
FITC conjugated peptides are used to check the binding specificity in confocal 
microscopy experiments. 
Different from cell binding studies, determination of the binding affinity is 
important as well. The binding affinity between a ligand and a receptor is widely 
determined by the equilibrium dissociation constant (KD). A high affinity means a strong 
binding which comes with a small KD. There are many solutions such as cell-based 
binding assays with FITC labeled peptides to find KD values in the receptor-ligand 
system. Additionally, competition assays with unlabeled and labeled peptides can be 
employed to obtain the binding constant. However, it is difficult to find the accurate 
mount of proteins on the cells performed in the experiments and this leads to inaccurate 
results of binding affinity. What’s more, some properties of the peptides can be changed 
when peptides are labeled with different agents, which means the function of these 
labeled agents is also unpredictable. 
There are many immunoassays such as Surface Plasmon Resonance (SPR), 
enzyme-linked immunosorbent assays (ELISA), and radioimmunoassay (RIA) for 
binding affinity studies. Surface Plasmon Resonance (SPR) is one of the quantitative 
approaches to observe real-time binding activity. SPR is an efficient label-free method 
that can be performed to calculate the equilibrium dissociation constant between two 
biomolecules in real time [116,117]. When an analyte binds to the target protein, there 
will be a change in the refractive index, resulting in the alteration in the resonance angle 




gold sensor chip is referred to as an analyte [118,119]. The real-time binding 
information can be obtained in SPR when it compares with fluorescent polarization 
study that is performed with the fluorescent probe for a relative binding constant. 
The binding specificity studies were performed by cellular uptake studies using 
two different cell lines including PD-L1 positive cell line, MDA-MB-231, and control 
cell lines, MCF-7. MDA-MB-231 is a breast cancer cell line known to express PD-L1 at 
a high level, and MCF-7 is also a breast cancer line used as a control for binding 
specificity studies [120]. After labeling with FITC, it is easy to determine whether they 
can bind specifically to PD-L1 positive cells and observe the visualization and location 
of the peptides by using confocal microscopy. Binding affinity can be determined by the 










A typical SPR set up is shown here in Figure 4.1. It has a light source, a prism, a 
golden chip, a flow channel, and a detector. The light source provides polarized light for 
the system. The prism can reflect the polarized light to different angles based on the 
binding conditions between the analytes and protein. The molecules immobilized in the 
golden chip and solution of analytes are injected in the flow channel. All the polarized 
light comes to the detector and becomes an SPR sensorgram. 
The light generated by the light source can hit the top of the sensor golden chip 
and prism. When analytes flow through the flow channel and bind to the target protein, 




the reflected light with the different angles caused by these changes in real time and the 
data can be shown in a sensorgram. 
 




A typical sensorgram is shown here in Figure 4.2. It has three main phases, the 
association phase, the equilibrium phase, and the dissociation phase. In the association 
phase, an increase in the SPR response signal is detected when the analyte starts to bind 
the immobilized protein. In the steady state, the binding sites become saturated and the 
response is unchanged for several seconds. This phase is called the equilibrium phase. 
After the equilibrium phase, a decrease in SPR response is observed which means the 





PD-L1 positive cells MDA-MB-231 and the control cell MCF-7 were purchased 
from ATCC (Manassas, VA, USA). The cells were cultured in Dulbecco’s modified 
eagle’s medium (DMEM) with 4.5g/L glucose, L-glutamine, and sodium pyruvate from 
Cellgro, Mediatech Inc (Manassas, VA, USA). Penicillin-Streptomycin was also 
obtained from Cellgro, Mediatech Inc. (Manassas, VA, USA). Trypsin: EDTA was 
bought from GEMINI (West Sacramento, CA, USA). Phosphate Buffered Saline (PBS) 
pH 7.2, hyclone Fetal Bovine Serum (FBS) was purchased from Thermo Scientific 
(Logan, UT, USA). Human PDL-1 Protein was purchased from Sino Biological Inc. 
(Beijing, China). All microscopy supplies were purchased from VWR (USA). Cell 
culture supplies were purchased from Santa Cruz Biotechnology Inc. (TX, USA) and 
Cellgro, Mediatech Inc. (Manassas, VA, USA). 
Alexa fluor 594 wheat germ agglutinin and Slow fade gold mounting medium 
were purchased from Invitrogen (Carlsbad, CA, USA). Phosphate buffered saline, pH 
7.4, contains TWEEN® 20, dry powder, N-ethyl-N’-(3-dimethylaminopropyl) 
carbodiimide (EDC), N-hydroxysuccinimide (NHS), Ethanolamine (EA), Glycine, and 
Bovine serum albumin (BSA) were purchased from Sigma-Aldrich (St. Louis, MO, 





4.3.1 Cell culture. DMEM was used as the cell culture media to which 10% FBS 
and 1% penicillin-streptomycin (5000 I.U./mL) were added and then refrigerated. MDA-
MB-231 and MCF-7 cells were incubated in a T75 flask in the prepared cell culture 
media at 37˚C and 5% CO2 and were subcultured when the cells reach 80% confluency. 
Additionally, cells were frozen in the recovery freezing media (DMEM with 5% DMSO) 
and stored in a nitrogen tank for future experiments. 
4.3.2 Confocal microscopy studies. MDA-MB-231 and MCF-7 cells were 
grown in T75 flasks at 37˚C and 5% CO2. 2× 105 cells were seeded on coverslips placed 
inside six well-cultured plates when the confluency reached about 80%. The experiment 
was carried out after 24 hours of attachment. After the medium was removed, the cells 
were washed twice with PBS and serum-free media. 
FITC labeled peptides and control peptide were dissolved and diluted in serum-
free DMEM with 1% dimethyl sulfoxide (DMSO). The final solutions of all peptides at 
the concentration of 20μM were added to the six well-cultured plates.  
After incubating for 25 minutes at 37˚C, the cells were washed twice with PBS 
and then treated with a solution of Alexa Fluor 594 wheat germ agglutinin in PBS at 2.5 
µg/mL for 10 minutes to stain the cell plasma membrane. After that, cells were washed 
twice with PBS and then fixed by 4% paraformaldehyde solution prepared in PBS for 15 
minutes. Then, a final wash of distilled water was performed after washing PBS twice. 
The coverslips with the fixed cells were covered on the microscopic slides with a drop of 




DMIRE2 confocal laser scanning microscope (Leica Biosystems Richmond Inc, 
Richmond, USA) with Yokogawa CSU-X1 confocal scanner unit at 64x magnification 
and oil immersion (Yokogawa Electric Corporation, Japan). The FITC labeled peptides 
were observed under the 491 nm channel, and the cell plasma membrane stained by 
Alexa Fluor 594 fluorescence was visualized under the 561 nm channel.  
A semiquantitative method of fluorescence intensity for peptides with salt bridge 
function was performed based on the cell images from confocal microscopy studies. The 
mean fluorescence intensity of ten cells in different cell images was determined and 




4.3.3 Binding affinity studies using SPR. The binding affinity of peptides was 
calculated by the Dual Channel SPR Spectrometer SPR7000DC (Reichert Technologies, 
New York, USA) in SPR studies. N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide 
hydrochloride (EDC) and N-hydroxysuccinimide (NHS) were employed to activate the 
Carboxymethyl Dextran Hydrogel Surface Sensor Chip (Reichert Technologies, New 
York, USA) under the running buffer of phosphate buffered saline with 0.05% Tween 20 
(pH7.4) that was degassed before using at room temperature. Then, ethanolamine (EA) 
pH 8.5 was injected to block unreactive sites for eight minutes at a rate of 10µL/min. 
Human PD-L1 protein (25µg/ml) and bovine serum albumin (BSA, 20µg/ml) were used 
as the control and were diluted and immobilized by flowing them over the left channel 
of the activated chip in 10 mM sodium acetate buffer pH 4.5. The real-time binding 
response for peptides (PDL1-01-25MER, PDL1-06-13MER, PDL1-P13-1, PDL1-P13-
28, PDL1-P13-33, PDL1-P13-40) over PD-L1 were observed at an injection speed of 
25µL/min in the SPR software. PDL1-P13-28 was also injected with BSA protein. 
Additionally, 10 mM glycine (pH 2.5) in PBST can be performed to regenerate the 
bound surface of the activated chips[193]. The sensorgrams from SPR were all analyzed 
using the Scrubber 2® software (BioLogic Software Pty Ltd, Australia) in the terms of 
zeroed, aligned, referenced, and blanked. The association rate (ka), dissociation rate 
(kd), and dissociation constant (KD) were also determined by using the Scrubber 2® 
software global in a 1:1 Lagmurian interaction model. 




Three generations of peptides against PD-L1 protein were designed based on the 
Knob-Socket model. After screening in MOE and the AutoDock Vina software, top 
peptides with lower energy were selected based on the docking results. Lower binding 
energy and more interaction sites with PD-L1 were also observed in the peptides 
designed in salt bridge function from MOE and the AutoDock Vina docking results. 
Experiments were performed to validate the docking results from the computational 
modeling method and test the binding specificity and affinity of the designed peptides. 
The affinity of the designed peptides to PD-L1 protein was determined in SPR 
studies. Response sensorgrams of three generations of peptides with PD-L1 collected 
from SPR studies are shown in Figure 4.3-4.9. All response sensorgrams were obtained 
from the Scrubber software.  
No binding responses for α-helix and over-packed peptides were observed in 
SPR sensorgram which suggested peptides designed in α-helix and over-packed method 
were not feasible. A reasonable explanation is the original α-helix design may have 
broken due to the improper position of knobs in the PD-L1 Knob-Socket receptor frame 
pattern and the low ratio of alpha-helical structure, resulting in the loss of knobs fit into 
their sockets for α-helix peptides. Additionally, due to the limited space, it is too 
congested for over-packed peptides to bind to the PD-L1 protein. 
When compared with the first and second generations of peptides which 
designed in α-helix and over-packed method, the third generation of peptides designed 
with the new binding information, salt bridge, had a much higher binding response. For 




sensorgram, while PDL1-P13-1, PDL1-P13-28, PDL1-P13-33, and PDL1-P13-40 had a 
response unit around 15. The SPR results of the response for third generation peptides 
toward the BSA protein is shown in Figure 4.9. From the results, we can find that 
peptides showed no binding to BSA protein, which means those designed peptides have 
a binding specificity. These data are a clear evidence that the third generations of 
peptides with salt bridge function can bind to the PD-L1 protein. However, KD values 
can’t be obtained since there was only a slight change when the concentrations of 
peptides increased. Though affinity of peptides against PD-L1 can’t be calculated, the 
binding between peptides and PD-L1 was further verified using the cell uptake 
experiments.  
The in vitro binding specificity of peptides to the PD-L1 positive cancer cells 
was determined in confocal microscopy studies. In confocal microscopy studies, 
significant fluorescence was detected on the cellular surfaces of MDA-MB-231, while 
no fluorescence was detected on MCF-7 cells from cell images (Figures 4.11-4.16) after 
incubation with 20 µM of FITC labeled peptides solution, which indicates that FITC 
conjugated peptides can bind to MDA-MB-231 but not to MCF-7 cells. On the contrary, 
no significant fluorescence was observed from both the two cell lines after incubation 
with FITC labeled control peptide with a scrambled sequence PDL1-P13-X solution. A 
plausible explanation is the knob and socket pairs may have broken, resulting in the loss 
of knobs fit into their sockets. To preserve the binding specificity, the peptide with 





The result of the significant fluorescence of MDA-MB-231 can be explained by 
the specific interaction between PD-L1 and designed peptides, which was consistent 
with the SPR results shown above.  
To determine the visualization and localization of the cell, the cell plasma 
membrane was marked by the Alexa Flour 594 dye in the confocal microscopy studies. 
First, free FITC was used to see whether it can go inside the cell lines, and in Figure 
4.10 results showed that free FITC can go inside both the two cell lines as a small 
molecule. In Figures 4.11-4.16, peptides showed internalization by cells instead of 
binding on the cell surface. The internalization of peptides can be attributed to receptor-
mediated endocytosis upon binding onto the PD-L1 protein. Additionally, peptides are 
much smaller when compared with antibodies, and as a result, it is much easier for 
peptides to internalize into cells. Results from the confocal microscopy studies 
suggested that the peptides with salt bridge function can bind to the PD-L1 positive cell 
lines but not to the control cell lines. 
A semiquantitative method of fluorescence intensity for peptides with salt bridge 
function was performed based on the cell images from confocal microscopy studies. The 
mean fluorescence intensity of ten cells in cell images for different peptides designed in 
salt bridge function was shown in Figure 4.17. There is a significant difference in 
fluorescence intensity between PD-L1 positive cell line and control cell line for peptides 
designed in salt bridge function, while a tiny difference for the FITC labeled control 
peptide with a scrambled sequence PDL1-P13-X. AutoDock Vina was used to perform a 




we can determine that only PDL1-P13-55 can bind to the designed part of the target 
protein. The PDL1-P13-55 with the lowest binding energy, which can bind to the 
designed part of the target protein based on the docking results from Vina, had a higher 
fluorescence intensity, when compared with the other five peptides in the figure, which 
indicates the potential of binding ability against PD-L1 Protein. 
The in vitro binding specificity of peptides towards PD-L1 was determined in the 
confocal microscopy and SPR studies. Results showed that the peptides with salt bridge 
function based on the Knob-Socket model and molecular interaction can bind to PD-L1 


































































Figure 4.10 Evaluation of binding specificity of Free FITC to MDA-MB-231 and MCF-7 cells as  
conformed by confocal microscopy.
















































Figure 4.11 Evaluation of binding specificity of FITC-PDL1-P13-01 to MDA-MB-231 and MCF-7 cells  
as conformed by confocal microscopy. 


































Figure 4.12 Evaluation of binding specificity of FITC-PDL1-P13-28 to MDA-MB-231 and MCF-7 cells  
as conformed by confocal microscopy. 















































Figure 4.13 Evaluation of binding specificity of FITC-PDL1-P13-33 to MDA-MB-231 and MCF-7 cells  
as conformed by confocal microscopy. 

















































Figure 4.14 Evaluation of binding specificity of FITC-PDL1-P13-40 to MDA-MB-231 and MCF-7 cells  
as conformed by confocal microscopy. 

















































Figure 4.15 Evaluation of binding specificity of FITC-PDL1-P13-55 to MDA-MB-231 and MCF-7 cells  
as conformed by confocal microscopy. 

















































Figure 4.16 Evaluation of binding specificity of FITC-PDL1-P13-X (control) to MDA-MB-231 and MCF-7  
cells as conformed by confocal microscopy. 
































































Chapter 5: Summary and Conclusions 
 
Programmed death-ligand 1 (PD-L1) is a type 1 transmembrane protein that has 
been reported to play a vital role in mediating suppressed immunity. The interaction 
between PD-L1 and PD-1 delivers a negative signal that reduces the proliferation of 
these T cells. Specific antibodies, peptides, and small molecules are developed by 
scientists to bind with PD-L1. Antibodies that can block the Programmed death-ligand 1 
(PD-L1) on tumor cells have shown to alleviate cancer-induced immunosuppression. 
While antibodies have a great potential in various therapeutic uses, many drawbacks 
such as high cost of production, huge molecular size, and poor permeability impose 
restrictions on the extensive use of full-length antibodies. Compared to antibodies, 
peptides that selectively bind to PD-L1 have advantages in solubility, permeability, and 
immunogenicity. The phage display technique or the computational screen of a large 
library of thousands of candidates are used to develop antibody alternatives. However, 
all these approaches are tedious, labor-intensive, and time-consuming due to their trial-
and-error nature. 
In this study, it is hypothesized that rationally designed peptides based on PD-
L1-PD1 molecular interactions and the Knob-Socket computational model can bind to 
PD-L1. Peptides against PD-L1 were designed based on the interaction between PD-L1 




peptides were obtained from the core amino acids in the binding surface between the 
PD-L1-PD1 complex by using the Knob-Socket model and further docked in MOE and 
Vina. The 2D map of peptides against PD-L1 with binding sites was obtained based on 
the Knob-Socket model. Three generations of peptides, α-helix, over-packed, and new 
peptides with the salt bridge function were designed and synthesized by using the Solid 
Phase Synthesis method (SPPS). The top 20% peptides were selected based on the 
binding energy simulated by MOE and AutoDock Vina before the binding affinity and 
specificity experiment. Peptide PDL1-P13-55 can bind to the right position which is 
designed to be bound based on the docking studies. The salt bridge function peptides 
with a lower binding energy and with a more number of interactions showed the binding 
preference against the PD-L1 protein, based on the docking results from MOE and 
AutoDock Vina. The binding between the designed peptides and PD-L1 was verified in 
vitro binding affinity and specificity experiments. The Surface Plasmon Resonance 
(SPR) technique was performed to determine the binding affinity of all the designed 
peptides. Only peptides with the salt bridge function have a high response while the α-
helix and over-packed peptides have no response on SPR sensorgrams. The confocal 
microscopic studies using different cell lines showed that third generations of peptides 
with salt bridge function bind specifically to PD-L1 positive cell line, MDA-MB-231, 
but not to PD-L1 control cell line, MCF-7. The salt bridge function peptides with a 
lower binding energy and with a more number of interactions selected based on the 





 towards PD-L1, which was confirmed based on the binding responses from SPR and the 
fluorescence intensity from confocal microscopic studies. 
In conclusion, peptides against PD-L1 designed rationally by the Knob-Socket 
model and the molecular interaction between the PD-L1-PD1 complex showed good 
binding specificity towards PD-L1, demonstrating the feasibility of this model in the 
design of binding ligands for targeting delivery. 
In the future, novel peptides can be used as a biomarker for the detection of PD-
L1 in various studies. The novel peptides can also be conducted as a targeting moiety of 
a peptide drug conjugate in PD-L1 positive cancers therapy. Cellular cytotoxicity studies 
can be performed to evaluate the potential of novel peptides to be used as targeting 
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